PD-L1+CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance - ScienceDirect
IRF-1 as a predictive marker for anti-PD-1 therapy. a IRF-1 expression... | Download Scientific Diagram
Effect of blocking PD-1 and PD-L1 on immune checkpoint and Treg-related... | Download Scientific Diagram
CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion | PLOS ONE
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy | PNAS
Frontiers | The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer | PNAS
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity | Nature
Frontiers | Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion | Nature Communications
PD-L1 expression on nonclassical monocytes reveals their origin and immunoregulatory function | Science Immunology
Role of PD-1 during effector CD8 T cell differentiation | PNAS
PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity | PLOS Pathogens
Release the B7.1! Anti-PD-L1 breaks PD-L1's grip
PD-1-high TILs: a predictive biomarker for ICB in lung cancer
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies | Nature Immunology
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer - ScienceDirect
Anti-PDL-1 Antibody Treatment Reduces Expression of the Exhaustion Marker PD -1 in T Cells | Biocompare Antibody Review
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy - ScienceDirect
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer - ScienceDirect
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors | Scientific Reports
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation - Pathology
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway | Abcam
Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma | Immunotherapy
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors | Molecular Cancer | Full Text
High IL-8 correlates with reduced response to PD-1/PD-L1 checkpoint blockade
